– SWITZERLAND, Zurich / USA, CA –  Vifor Pharma Group (SWX:VIFN) today announced the appointment of Patrick Treanor to the Executive Committee of Vifor Pharma Group with immediate effect and as President of Relypsa on a permanent basis. Patrick was appointed interim President of Relypsa, the US affiliate of Vifor Pharma Group on 20 September 2018.

About Patrick Treanor

Patrick joined Relypsa in 2015 to establish the sales organisation for the US launch of Veltassa®. In April 2017, he was appointed Senior Vice President and Chief Commercial Officer of Relypsa and has been instrumental in leading the commercialisation strategy of Veltassa® and driving Relypsa to achieve its goal of becoming a leader in nephrology and cardio-renal therapies.

About Vifor Pharma Group

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care.

Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma.

Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN).

For more, visit www.viforpharma.com.

About Relypsa, Inc.

Relypsa, Inc., a Vifor Pharma Group company, is a biopharmaceutical company focused on the development and commercialization of late-stage medicines in the iron deficiency, nephrology and cardio-renal therapeutic areas. Relypsa is committed to delivering innovative therapies and improving the lives of patients with serious and life-threatening conditions that are often overlooked and undertreated. The company’s first medicine, Veltassa® (patiromer) for oral suspension, was approved by the U.S. FDA in October 2015, making it the first approved medicine for the treatment of hyperkalaemia in more than 50 years.

For more, visit www.relypsa.com.

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.